IgGenix is a clinical-stage, venture backed company using single cell transcriptomics to isolate rare IgE producing B cells directly from patients and discover novel antibody therapeutics. Our lead program for peanut allergy has completed its P1 POC study. We are seeking new investors for our Series C.